Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide

被引:404
作者
Lu, Jun [1 ]
Chew, Eng-Hui [1 ]
Holmgren, Arne [1 ]
机构
[1] Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden
关键词
glutathione; reactive oxygen species; oxidative stress; cell death;
D O I
10.1073/pnas.0701549104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Arsenic trioxide (ATO) is an effective cancer therapeutic drug for acute promyelocytic leukemia and has potential anticancer activity against a wide range of solid tumors. ATO exerts its effect mainly through elevated oxidative stress, but the exact molecular mechanism remains elusive. The thioredoxin (Trx) system comprising NADPH, thioredoxin reductase (TrxR), and Trx and the glutathione (GSH) system composed of NADPH, gluitathione reductase, and GSH supported by glutaredoxin are the two electron donor systems that control cellular proliferation, viability, and apoptosis. Recently, the selenocysteine-dependent TrxR enzyme has emerged as an important molecular target for anticancer drug development. Here, we have discovered that ATO irreversibly inhibits mammalian TrxR with an lC(50) of 0.25 mu M. Both the N-terminal redox-active dithiol and the C-terminal selenothiol-active site of reduced TrxR may participate in the reaction with ATO. The inhibition of MCF-7 cell growth by ATO was correlated with irreversible inactivation of TrxR, which subsequently led to Trx oxidation. Furthermore, the inhibition of TrxR by ATO was attenuated by GSH, and GSH depletion by buthionine sulfoximine enhanced ATO-induced cell death. These results strongly suggest that the ATO anticancer activity is by means of a Trx system-mediated apoptosis. Blocking cancer cell DNA replication and repair and induction of oxidative stress by the inhibition of both Trx and GSH systems are suggested as cancer chemotherapeutic strategies.
引用
收藏
页码:12288 / 12293
页数:6
相关论文
共 70 条
  • [1] Akay C, 2004, CELL CYCLE, V3, P324
  • [2] The thioredoxin system in cancer
    Arner, Elias S. J.
    Holmgren, Arne
    [J]. SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) : 420 - 426
  • [3] Physiological functions of thioredoxin and thioredoxin reductase
    Arnér, ESJ
    Holmgren, A
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20): : 6102 - 6109
  • [4] High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes
    Arnér, ESJ
    Sarioglu, H
    Lottspeich, F
    Holmgren, A
    Böck, A
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1999, 292 (05) : 1003 - 1016
  • [5] Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex
    Arnér, ESJ
    Nakamura, H
    Sasada, T
    Yodoi, J
    Holmgren, A
    Spyrou, G
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 (10) : 1170 - 1178
  • [6] Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825
  • [7] Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658
  • [8] Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects
    Baj, G
    Arnulfo, A
    Deaglio, S
    Mallone, R
    Vigone, A
    De Cesaris, MG
    Surico, N
    Malavasi, F
    Ferrero, E
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 73 (01) : 61 - 73
  • [9] Crystal structures of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of the reaction mechanism
    Biterova, EI
    Turanov, AA
    Gladyshev, VN
    Barycki, JJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (42) : 15018 - 15023
  • [10] Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
    Cai, X
    Shen, YL
    Zhu, Q
    Jia, PM
    Yu, Y
    Zhou, L
    Huang, Y
    Zhang, JW
    Xiong, SM
    Chen, SJ
    Wang, ZY
    Chen, Z
    Chen, GQ
    [J]. LEUKEMIA, 2000, 14 (02) : 262 - 270